Cancer Biomarkers Market worth $42.0 billion by 2029
According to recent research report the report Cancer Biomarkers Market is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
Increasing
incidence of cancer followed by awareness for early diagnosis, growing
investments in research and development of cancer biomarkers, extensive
use of these biomarkers for diagnosis, drug discovery and development
are the key factors responsible for growth of this market.Companies in
the market for optometry equipment are finding that developing nations
like China, Japan, and India provide attractive opportunities.
According to the profiling technology segment, the omics technology held the biggest market share for cancer biomarkers.”
The
market for cancer biomarkers has been divided into two segments based
on profiling methods: omics technologies and imaging technologies. As of
2023, the cancer biomarkers market was dominated by the omics
technology segment, mainly due to high throughput nature of these
technologies in cancer biomarker discovery and diagnosis.
Throughout the projection period, the breast cancer segment is expected to develop at the fastest rate.
The
market for cancer biomarkers is divided into categories according to
the kind of cancer: non-Hodgkin's lymphoma, kidney cancer, bladder
cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer,
prostate cancer, melanoma, leukemia, thyroid cancer, and other cancer
types. The market for cancer biomarkers was dominated in 2023 by the
breast cancer segment. The huge share of this segment is due to the
growing rate of breast cancer cases worldwide followed by awareness for
diagnosis for prevention and treatment.
The instruments segment held the largest share in the market, by product”.
The
cancer biomarker market is divided into three segments based on
product: instruments, consumables, and bioinformatics software. In 2023,
the instruments segment hold the major market due to continuous need
for cancer detection, improvements in instrument technology and high
accuracy detection methods .
By application category, the cancer biomarkers market held the biggest share in 2023 for the diagnostics segment.
The
market for cancer biomarkers has been divided into segments based on
application, including risk assessment, prognostics, diagnostics, and
research & development. As of 2023, the cancer biomarkers market was
dominated by the diagnostics sector, primarily due to the increase in
cancer incidence, increased awareness and acceptance of diagnostic tests
and increase in technologically advanced biomarker products.
“North America aimed for the largest share of the optometry equipment market”.
The
global cancer biomarkers market is segmented into six major
regions—North America, Europe, the Asia Pacific, Latin America, the
Middle East & Africa and GCC Countries. North America is the largest
regional market for cancer biomarkers. The large share of North America
in this market can be attributed to the increasing prevalence of
cancer, increasing research on cancer biomarkers, technological
advancements, and the increasing use of cancer biomarkers in drug
discovery and development.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202
The
major players leading in cancer biomarkers market are F. Hoffmann-La
Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN
N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc.
(US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson
and Company (US), Merck Millipore (US), Agilent Technologies (US),
Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc.
(US), Quest Diagnostics (US), Centogene N.V. (Germany).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment